Article de revue
Cancer-salient messaging for Human Papillomavirus vaccine uptake: A randomized controlled trial
Vaccination with Human Papillomavirus (HPV) vaccine is recommended for 11–12 years-old, but uptake is suboptimal. Current messaging focuses on HPV infection transmission and prevention. Parents and providers are often uncomfortable discussing sexual practices of adolescents, contributing to the delay/refusal of vaccine. We created a cervical cancer-salient message encouraging HPV vaccination, emphasizing disease salience and disease threat, while promoting self-efficacy. We hypothesized this message would have greater effects on vaccine confidence and intent to vaccinate compared to Centers for Disease Control and Prevention (CDC) and non-vaccine control messages
Langues
- Anglais
Année de publication
2018
Journal
Vaccine
Volume
36
Numéro
18
Type
Article de revue
Catégories
- Prestation de services
Maladies
- Papillomavirus humain
Mots-clés
- Suivi de la couverture
- Introduction de nouveaux vaccins